BLPH - Bellerophon Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development19,55917,15416,25032,965
Selling General and Administrative8,3217,4457,50715,270
Non Recurring----
Total Operating Expenses27,88024,59923,75746,568
Operating Income or Loss-27,880-24,599-23,757-46,568
Income from Continuing Operations
Total Other Income/Expenses Net25,255-30,219-143109
Earnings Before Interest and Taxes-27,880-24,599-23,757-46,568
Interest Expense----
Income Before Tax-2,625-54,818-24,252-46,459
Income Tax Expense-5,439--438-
Minority Interest----
Net Income From Continuing Ops2,814-54,818-23,814-46,459
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income2,814-54,818-23,814-46,459
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares2,814-54,818-23,814-46,459